What is the current stock price of Evelo Biosciences, Inc. (EVLO)?

As of the latest market data, Evelo Biosciences, Inc. (EVLO) is trading at $0.00. The stock has seen a loss of 0.00% today.

Does Evelo Biosciences, Inc. (EVLO) pay a dividend?

Based on current data, Evelo Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Evelo Biosciences, Inc.?

The current market capitalization of Evelo Biosciences, Inc. (EVLO) is approximately unavailable.

EVLO

Evelo Biosciences, Inc.·Healthcare

0.00

0.000%(+0.00)

Close Price

0.30

300000.000%(+0.30)

After Hours

Last Updated: — ET

52W L: $0.0052W H: $0.00

EVLO NEWS

defenseworld.net

Apr 2

Stock Traders Buy Large Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 1,885 put options on the stock. This represents an increase of 1,101% compared to the average volume of 157 put options. Evelo Biosciences Stock Performance Evelo Biosciences has a 1 year low of $0.00 and

defenseworld.net

Mar 19

Head to Head Review: Evelo Biosciences (NASDAQ:EVLO) vs. Silverback Therapeutics (NASDAQ:SBTX)

Profitability This table compares Silverback Therapeutics and Evelo Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Evelo Biosciences N/A N/A N/A Valuation and Earnings This table compares Silverback Therapeutics and Evelo Biosciences"s top-line revenue, earnings per share (EPS) and valuation.

Company Profile

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-05-08

Beta

1.67

Websitewww.evelobio.com↗